Clinical trial · Pediatric← The news desk

✦ The Dispatch

Skylark Bio Receives Green Light to Expand Pediatric Hearing Loss Gene Therapy Trial

A dispatch from Hearing Health Matters — filed

Skylark Bio company logo in white text on a deep blue background, with a digital wireframe ear graphic on the right side.
✦ PlateSkylark Bio company logo in white text on a deep blue background, with a digital wireframe ear graphic on the right side.

CAMBRIDGE, MASSACHUSETTS — Skylark Bio announced that an independent Data Safety Monitoring Board (DSMB) has unanimously recommended advancing its investigational gene therapy, SKY-GJB2, into the next stage of the SONIX Phase 1/2 clinical trial. The decision follows a review of safety data from the first four children treated in the study, allowing researchers to begin enrolling younger participants....

Continue reading at Hearing Health Matters

✦ The floor

Discussion

Signed responses from readers of the wire.

✦ Clinical Takeaway ✦

No actionable clinical change yet — this is an early-phase (Phase 1/2) safety trial and no efficacy data are available; audiologists should monitor for future results.

✦ Why It Matters ✦

Progression of GJB2-targeted gene therapy into expanded pediatric trials represents a potential paradigm shift toward biological hearing restoration for the most common form of genetic hearing loss.

✦ Key Points ✦
  1. 01Skylark Bio's independent Data Safety Monitoring Board (DSMB) unanimously approved advancing the SKY-GJB2 gene therapy trial.
  2. 02The trial is the SONIX Phase 1/2 study targeting GJB2-related pediatric hearing loss.
  3. 03GJB2 mutations are the most common genetic cause of congenital hearing loss.
  4. 04DSMB advancement indicates no major safety signals in the initial cohort.
  5. 05Trial remains in early phase; efficacy and long-term outcomes are not yet established.
✦ Claims & Evidence ✦

The independent DSMB unanimously recommended advancing SKY-GJB2 to the next stage of the SONIX Phase 1/2 trial.

press releasesupported

SKY-GJB2 is a gene therapy targeting pediatric hearing loss caused by GJB2 mutations.

press releasesupported
✦ Research metadata ✦
Publication type
clinical_trial
Evidence level
4
Population
Pediatric patients with hearing loss due to GJB2 gene mutations
Intervention
SKY-GJB2 gene therapy

Primary outcomes

Safety and tolerability; Advancement criteria for next trial stage

✦ Related stories ✦